Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD

[1]  R. Elashoff,et al.  Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. , 2013, Respiratory medicine.

[2]  Yufeng Liu,et al.  Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT®). , 2013, Respiratory medicine.

[3]  L. Edwards,et al.  Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease , 2012, Thorax.

[4]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[5]  M. Decramer,et al.  Bronchodilator responsiveness in patients with COPD , 2008, European Respiratory Journal.

[6]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[7]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[8]  N. Anthonisen,et al.  Bronchodilator response in the lung health study over 11 yrs , 2005, European Respiratory Journal.

[9]  J. Donohue.  Therapeutic responses in asthma and COPD. Bronchodilators. , 2004, Chest.

[10]  P. Paré,et al.  The nature of small-airway obstruction in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[11]  M. Decramer,et al.  Clinical Trial Design Considerations in Assessing Long‐Term Functional Impacts of Tiotropium in COPD: The Uplift Trial , 2004, COPD.

[12]  S. Spencer,et al.  Bronchodilator reversibility testing in chronic obstructive pulmonary disease , 2003, Thorax.

[13]  D. Tashkin,et al.  Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. , 2003, Chest.

[14]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[15]  P. Dorinsky,et al.  The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. , 1999, Chest.

[16]  S. Yancey,et al.  Efficacy of salmeterol xinafoate in the treatment of COPD. , 1999, Chest.

[17]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[18]  J. Earis,et al.  Acute bronchodilator trials in chronic obstructive pulmonary disease. , 1992, The American review of respiratory disease.

[19]  N. Anthonisen,et al.  Prognosis in chronic obstructive pulmonary disease. , 1990, The American review of respiratory disease.

[20]  Anthonisen Nr,et al.  Bronchodilator response in chronic obstructive pulmonary disease. , 1986 .

[21]  N. Anthonisen,et al.  Bronchodilator response in chronic obstructive pulmonary disease. , 1986, The American review of respiratory disease.

[22]  J. Mead,et al.  Elasticity of human lungs in relation to age. , 1968, Journal of applied physiology.